PF-Atlas › Clinical Trials › NCT00256555
Growth Hormone Treatment Study in Children With Cystic Fibrosis
Nutropin AQ · Phase 2
Registry ID
NCT00256555
Phase
Phase 2
Status
Withdrawn
Drug / intervention
Nutropin AQ
Sponsor
University of Texas Southwestern Medical Center
Start
2000-02
About this trial
Cystic fibrosis (CF) is a catabolic condition, and children affected with this disease frequently have problems with growth, despite adequate nutrition. We hypothesize that the anabolic effects of growth hormone (GH) will improve the height and weight of CF patients and thereby improve their clinical status and their quality of life. We further hypothesize that these effects will be sustained for at least one year after GH treatment is complete.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT00256555 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.